- Home
- ZLAB
ZLAB
Zai Lab Limited
as of 03-19-2026 3:56pm EST
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
| Founded: | 2013 | Country: | China |
| Employees: | N/A | City: | SHANGHAI |
| Market Cap: | 1.8B | IPO Year: | 2017 |
| Target Price: | $49.60 | AVG Volume (30 days): | 543.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.16 | EPS Growth: | 38.46 |
| 52 Week Low/High: | $15.96 - $44.34 | Next Earning Date: | 05-07-2026 |
| Revenue: | $460,156,000 | Revenue Growth: | 15.33% |
| Revenue Growth (this year): | 14.46% | Revenue Growth (next year): | 29.47% |
| P/E Ratio: | -118.05 | Index: | N/A |
| Free Cash Flow: | -158890000.0 | FCF Growth: | N/A |
AI-Powered ZLAB Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Zai Lab Limited (ZLAB)
Director
Avg Cost/Share
$18.91
Shares
1,731
Total Value
$32,733.21
Owned After
56,630
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$18.63
Shares
1,703
Total Value
$31,723.48
Owned After
19,999
SEC Form 4
See Remarks
Avg Cost/Share
$18.63
Shares
1,966
Total Value
$36,622.65
Owned After
91,026
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$18.63
Shares
1,281
Total Value
$23,862.47
Owned After
6,494
SEC Form 4
See Remarks
Avg Cost/Share
$18.63
Shares
2,957
Total Value
$55,083.00
Owned After
44,757
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$19.06
Shares
15,569
Total Value
$296,745.14
Owned After
6,494
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| GAYNOR RICHARD | ZLAB | Director | Mar 17, 2026 | Buy | $18.91 | 1,731 | $32,733.21 | 56,630 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Mar 13, 2026 | Sell | $18.63 | 1,703 | $31,723.48 | 19,999 | |
| Smiley Joshua L | ZLAB | See Remarks | Mar 13, 2026 | Sell | $18.63 | 1,966 | $36,622.65 | 91,026 | |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Mar 13, 2026 | Sell | $18.63 | 1,281 | $23,862.47 | 6,494 | |
| Amado Rafael | ZLAB | See Remarks | Mar 13, 2026 | Sell | $18.63 | 2,957 | $55,083.00 | 44,757 | |
| Du Ying | ZLAB | Chairperson & CEO | Mar 11, 2026 | Sell | $19.08 | 1,067 | $20,362.63 | 1,109,905 | |
| Du Ying | ZLAB | Chairperson & CEO | Mar 9, 2026 | Sell | $19.03 | 50,000 | $951,465.00 | 1,109,905 | |
| Du Ying | ZLAB | Chairperson & CEO | Mar 6, 2026 | Sell | $19.42 | 50,000 | $970,935.00 | 1,109,905 | |
| Du Ying | ZLAB | Chairperson & CEO | Mar 5, 2026 | Sell | $19.22 | 50,000 | $961,055.00 | 1,109,905 | |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Mar 5, 2026 | Sell | $19.06 | 15,569 | $296,745.14 | 6,494 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 26, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 26, 2026 · 100% conf.
1D
+3.72%
$20.42
Act: -2.49%
5D
+10.26%
$21.71
Act: -1.85%
20D
+8.97%
$21.46
zlab-20260226false000170429200017042922026-02-262026-02-260001704292dei:AdrMember2026-02-262026-02-260001704292us-gaap:CommonStockMember2026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026
ZAI LAB LIMITED
(Exact name of registrant as specified in its charter)
Cayman Islands001-3820598-1144595 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
899 Halei Road Building B, Pudong Shanghai, China 201203
314 Main Street 4th Floor, Suite 100 Cambridge, MA, USA02142 (Address of principal executive offices)(Zip Code)
+86 21 6163 2588 +1 857 706 2604 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s) Name of each exchange on which registered
American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per shareZLABThe Nasdaq Global Market Ordinary Shares, par value $0.000006 per share*9688The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 26, 2026, Zai Lab Limited issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information contained in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1Press Release issued by Zai Lab Limited on February 26, 2026
104The cover page of this report is formatted in Inline XBRL
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZAI LAB LIMITED
By:/s/ Yajing Chen Yajing Chen
Chief Financial Officer
Date: February 26, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
Q3 2025 Earnings
8-KNov 6, 2025
zlab-20251106false000170429200017042922025-11-062025-11-060001704292dei:AdrMember2025-11-062025-11-060001704292us-gaap:CommonStockMember2025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
ZAI LAB LIMITED
(Exact name of registrant as specified in its charter)
Cayman Islands001-3820598-1144595 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
899 Halei Road Building B, Pudong Shanghai, China 201203
314 Main Street 4th Floor, Suite 100 Cambridge, MA, USA02142 (Address of principal executive offices)(Zip Code)
+86 21 6163 2588 +1 857 706 2604 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s) Name of each exchange on which registered
American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per shareZLABThe Nasdaq Global Market Ordinary Shares, par value $0.000006 per share*9688The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Zai Lab Limited issued a press release announcing its financial results for the third quarter of 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information contained in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1Press Release issued by Zai Lab Limited on November 6, 2025
104The cover page of this report is formatted in Inline XBRL
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZAI LAB LIMITED
By:/s/ Yajing Chen Yajing Chen
Chief Financial Officer
Date: November 6, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
Q2 2025 Earnings
8-KAug 7, 2025
zlab-20250807false000170429200017042922025-08-072025-08-070001704292dei:AdrMember2025-08-072025-08-070001704292us-gaap:CommonStockMember2025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025
ZAI LAB LIMITED
(Exact name of registrant as specified in its charter)
Cayman Islands001-3820598-1144595 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
899 Halei Road Building B, Pudong Shanghai, China 201203
314 Main Street 4th Floor, Suite 100 Cambridge, MA, USA02142 (Address of principal executive offices)(Zip Code)
+86 21 6163 2588 +1 857 706 2604 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s) Name of each exchange on which registered
American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per shareZLABThe Nasdaq Global Market Ordinary Shares, par value $0.000006 per share*9688The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Zai Lab Limited issued a press release announcing its financial results for the second quarter of 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information contained in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1Press Release issued by Zai Lab Limited on August 7, 2025
104The cover page of this report is formatted in Inline XBRL
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZAI LAB LIMITED
By:/s/ Yajing Chen Yajing Chen
Chief Financial Officer
Date: August 7, 2025
Compare ZLAB vs Leading Stocks
See how ZLAB stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ZLAB Zai Lab Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.